| __timestamp | Celldex Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 570979 |
| Thursday, January 1, 2015 | 4011000 | 2185000 |
| Friday, January 1, 2016 | 102026000 | 4554000 |
| Sunday, January 1, 2017 | 96171000 | 3605000 |
| Monday, January 1, 2018 | 66449000 | 5527000 |
| Tuesday, January 1, 2019 | 42672000 | 5234000 |
| Wednesday, January 1, 2020 | 42534000 | 6126000 |
| Friday, January 1, 2021 | 3068000 | 6784000 |
| Saturday, January 1, 2022 | 1400000 | 7592000 |
| Sunday, January 1, 2023 | 3008000 | 11450000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for two prominent players: Celldex Therapeutics, Inc. and Travere Therapeutics, Inc., from 2014 to 2023.
Celldex Therapeutics, Inc. experienced a significant fluctuation in its cost of revenue, peaking in 2014 and 2016 with over 100 million, before witnessing a dramatic decline of nearly 98% by 2022. In contrast, Travere Therapeutics, Inc. showed a steady increase, with costs rising by approximately 1,900% over the same period, reaching their highest in 2023.
These contrasting trends highlight the diverse financial strategies and market conditions faced by biotech firms. As the industry evolves, such insights are invaluable for making informed decisions in a competitive landscape.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Pfizer Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sanofi and Travere Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Viatris Inc. vs Travere Therapeutics, Inc.
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.
Pharming Group N.V. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Analyzing Cost of Revenue: MorphoSys AG and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.